Download PDF
kleintier konkret 2015; 18(1): 12-18
DOI: 10.1055/s-0034-1384499
hund
kardiologie
Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Mitralklappenerkrankung des Hundes im asymptomatischen Stadium: Behandeln oder nicht behandeln?

Sonja Schiller
Fachtierärztin für Innere Medizin der Kleintiere, Zusatzbezeichnung Kardiologie, Mitglied des Collegium Cardiologicum, Mobile Kleintier-Kardiologie
› Author Affiliations
Further Information

Publication History

Publication Date:
12 March 2015 (online)

Also available at
   Permissions and Reprints All articles of this category

Die Mitralklappenendokardiose ist die häufigste Herzerkrankung des Hundes. Oftmals ist sie durch einen jahrelangen präklinischen Verlauf gekennzeichnet und gerade die Behandlung dieses asymptomatischen Stadiums wird selbst in Fachkreisen kontrovers diskutiert. Die folgende Veröffentlichung gibt eine aktuelle Literaturübersicht zur Behandlung der Mitralendokardiose im asymptomatischen Stadium. Sie soll dem Praktiker eine therapeutische Entscheidung nach aktuellstem Wissensstand erleichtern.

 

  • Literatur

  • 1 Atkins C, Keene BW, Brown WA. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007; 231 (7): 1061-1069
    CrossrefGoogle Scholar
  • 2 Atkins C, Bonagura J, Ettinger S et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23 (6): 1142-1150
    CrossrefGoogle Scholar
  • 3 Atkins C, Häggström J. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol 2012; 14 (1): 165-184
    CrossrefGoogle Scholar
  • 4 Bavegems V, Van Caelenberg A, Duchateau L et al. Vertebral heart size ranges specific for whippets. Vet Radiol Ultrasound 2005; 46 (5): 400-403
    CrossrefGoogle Scholar
  • 5 Beardow AW, Buchanan JW. Chronic mitral valve disease in cavalier King Charles spaniels: 95 cases (1987–1991). J Am Vet Med Assoc 1993; 203 (7): 1023-1029
    Google Scholar
  • 6 Bernay F, Bland JM, Häggström J et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24 (2): 331-341
    CrossrefGoogle Scholar
  • 7 Borgarelli M, Crosara S, Lamb K et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med 2012; 26 (1): 69-75
    CrossrefGoogle Scholar
  • 8 Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995; 206 (2): 194-199
    Google Scholar
  • 9 Buchanan J. Prevalence of cardiovascular disorders. In: Fox PR, Sisson DD, Moise N, eds. Textbook of Canine and Feline Cardiology. Philadelphia: Saunders; 1999
    Google Scholar
  • 10 Chetboul V, Lefebvre HP, Sampedrano CC et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007; 21 (4): 742-253
    CrossrefGoogle Scholar
  • 11 Chetboul V, Serres F, Tissier R et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009; 23 (5): 984-994
    CrossrefGoogle Scholar
  • 12 Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103 (4): 425-431
    CrossrefGoogle Scholar
  • 13 Gelzer AR, Kraus MS, Rishniw M et al. Combination therapy with digoxin and diltiazem controls ventricular rate in chronic atrial fibrillation in dogs better than digoxin or diltiazem monotherapy: a randomized crossover study in 18 dogs. J Vet Intern Med 2009; 23 (3): 499-508
    CrossrefGoogle Scholar
  • 14 Häggström J, Hansson K, Karlberg BE et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996; 57 (11): 1645-1652
    Google Scholar
  • 15 Häggström J, Hansson K, Kvart C et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997; 58 (1): 77-82
    Google Scholar
  • 16 Häggström J, Boswood A, O’Grady M et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22 (5): 1124-1235
    CrossrefGoogle Scholar
  • 17 Häggström J, Boswood A, O’Grady M et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. J Vet Intern Med 2013; 27 (6): 1441-1451
    CrossrefGoogle Scholar
  • 18 Hansson K, Häggström J, Kvart C et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002; 43 (6): 568-575
    CrossrefGoogle Scholar
  • 19 Hezzell MJ, Boswood A, Elliott J. Treatment of dogs with compensated degenerative mitral valve disease (DMVD) with spironolactone. Maastricht: ECVIM-CA Congress 2012 Im Internet: http://www.vin.com/Members/Proceedings/Proceedings.plx?CID=ECVIM2012&PID=pr84851&O=Generic Stand: 11/2014
    Google Scholar
  • 20 Hungerbühler S, Henrich E. Die Mitralklappenendokardiose – aktueller Stand der Diagnose und Therapie. Kleintierprax 2014; 59 (6): 329-352
    Google Scholar
  • 21 Hunt SA, Abraham WT, Chin MH et al. Focused update incorporated into the ACC/AHA 2005. Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 2009; 53 (15): e1-e90
    CrossrefGoogle Scholar
  • 22 Jepsen-Grant K, Pollard RE, Johnson LR. Vertebral heart scores in eight dog breeds. Vet Radiol Ultrasound 2013; 54 (1): 3-8
    CrossrefGoogle Scholar
  • 23 Kittleson M, Rishniw M, Pion P et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 2009; 23 (3): 445-446; author reply 447–448
    CrossrefGoogle Scholar
  • 24 Kittleson MD, Bonagura JD. Re: Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24 (6): 1245-1256 author reply 1247–1248
    CrossrefGoogle Scholar
  • 25 Kraetschmer S, Ludwig K, Meneses F et al. Vertebral heart scale in the beagle dog. J Small Anim Pract 2008; 49 (5): 240-243
    CrossrefGoogle Scholar
  • 26 Kvart C, Häggström J, Pedersen HD et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002; 16 (1): 80-88
    CrossrefGoogle Scholar
  • 27 Lamb CR, Wikeley H, Boswood A et al. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001; 148 (23): 707-711
    CrossrefGoogle Scholar
  • 28 Lantis AC, Atkins CE, DeFrancesco TC. Aldosterone escape in furosemide-activated circulating renin-angiotensin-aldosterone system (RAAS) in normal dogs. J Vet Intern Med 2010; 24: 672
    Google Scholar
  • 29 Lefebvre HP, Olliver E, Atkins CE et al. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. J Vet Intern Med 2013; 27 (5): 1083-1091
    CrossrefGoogle Scholar
  • 30 Marcondes-Santos M, Tarasoutchi F, Mansur AP et al. Effects of carvedilol treatment in dogs with chronic mitral valvular disease. J Vet Intern Med 2007; 21 (5): 996-1001
    CrossrefGoogle Scholar
  • 31 Marin LM, Brown J, McBrien C et al. Vertebral heart size in retired racing Greyhounds. Vet Radiol Ultrasound 2007; 48 (4): 332-334
    Google Scholar
  • 32 Moonarmart W, Boswood A, Luis Fuentes V et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010; 51 (2): 84-96
    CrossrefGoogle Scholar
  • 33 Ouellet M, Bélanger MC, Difruscia R et al. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med 2009; 23 (2): 258-263
    CrossrefGoogle Scholar
  • 34 Ovaert P, Elliott J, Bernay F et al. Aldosterone receptor antagonists – how cardiovascular actions may explain their beneficial effects in heart failure. J Vet Pharmacol Ther 2010; 33 (2): 109-117
    CrossrefGoogle Scholar
  • 35 Oyama MA. Neurohormonal activation in canine degenerative mitral valve disease: implications on pathophysiology and treatment. J Small Anim Pract 2009; 50 (Suppl 1): 3-11
    CrossrefGoogle Scholar
  • 36 Oyama MA, Levy RJ. Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease. J Vet Intern Med 2010; 24 (1): 27-36
    CrossrefGoogle Scholar
  • 37 Pedersen HD, Koch J, Poulsen K et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Intern Med 1995; 9 (5): 328-331
    CrossrefGoogle Scholar
  • 38 Pitt B. „Escape“ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9 (1): 145-149
    CrossrefGoogle Scholar
  • 39 Pouchelon JL, Jamet N, Gouni V et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 2008; 22 (4): 905-914
    CrossrefGoogle Scholar
  • 40 Reynolds CA, Brown DC, Rush JE et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14 (1): 193-202
    CrossrefGoogle Scholar
  • 41 Schober KE, Hart TM, Stern JA et al. Detection of congestive heart failure in dogs by Doppler echocardiography. J Vet Intern Med 2010; 24 (6): 1358-1368
    CrossrefGoogle Scholar
  • 42 Schober KE, Hart TM, Stern JA et al. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011; 239 (4): 468-479
    CrossrefGoogle Scholar
  • 43 Tarnow I, Olsen LH, Kvart C et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009; 180 (2): 195-201
    CrossrefGoogle Scholar
  • 44 Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89 (2A): 3A-9A discussion 10A
    Google Scholar
  • 45 Urabe Y, Mann DL, Kent RL et al. Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation. Circ Res 1992; 70 (1): 131-147
    CrossrefGoogle Scholar
  • 46 Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Circulation 1991; 83 (6): 1849-1865
    Google Scholar